ESR1 and lung carcinoma: Indeed, both drugs significantly sensitized tumor cells to fractionated IR and an accelerated sensitivity to chemotherapy after administration of Fulvestrant was demonstrated recently for of estrogen receptor positive breast and lung cancer cells [37, 38].